PARKINInactivation Links Parkinson’s Disease to Melanoma
Author(s) -
HuiHan Hu,
Caroline Kannengiesser,
Suzanne Lesage,
Jocelyne André,
Samia Mourah,
Laurence Michel,
V. Descamps,
Nicole BassetSéguin,
M. Bagot,
Armand Bensussan,
Célèste Lebbé,
Lydia Deschamps,
Philippe Saïag,
M.T. Leccia,
Brigitte Bressac–de Paillerets,
A. Tsalamlal,
Rajiv Kumar,
Stephan Klebe,
Bernard Grandchamp,
Nathalie AndrieuAbadie,
L. Thomas,
Alexis Brice,
Nicolas Dumaz,
Nadem Soufir
Publication year - 2015
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djv340
Subject(s) - parkin , melanoma , cancer research , biology , loss of heterozygosity , neuroblastoma ras viral oncogene homolog , tumor suppressor gene , genetics , mutation , allele , parkinson's disease , carcinogenesis , medicine , cancer , pathology , gene , disease , kras
Melanoma incidence is higher in patients affected by Parkinson's disease (PD) and vice versa, but the genetic link shared by both diseases is unknown. As PARK2 is both a tumor suppressor gene and frequently mutated in young onset PD, we evaluated the role of PARK2 in melanoma predisposition and progression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom